NCT03681275 is a Phase 2 clinical trial of Tofacitinib 10 MG [Xeljanz] in Diaphragm Injury, sponsored by Stanford University.

Who is sponsoring NCT03681275?

NCT03681275 is sponsored by Stanford University.

What drugs are being tested in NCT03681275?

Interventions in NCT03681275: Tofacitinib 10 MG [Xeljanz], Placebo to match Tofacitinib.

What condition does NCT03681275 study?

NCT03681275 studies Diaphragm Injury.

Is NCT03681275 still recruiting?

NCT03681275 is currently recruiting now. Last updated 25 November 2024.

Last reviewed 2024-11-25 · How we verify

NCT03681275

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Recruiting now Phase 2 Last updated 25 November 2024

What this trial tests

Phase 2 trial testing Tofacitinib 10 MG [Xeljanz] in Diaphragm Injury in 70 participants. Currently enrolling.

Timeline

3 September 2019

Primary endpoint
30 November 2025

30 November 2026

Quick facts

Lead sponsor	Stanford University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	70
Start date	3 September 2019
Primary completion	30 November 2025
Estimated completion	30 November 2026
Sites	1 location across United States

Drugs / interventions tested

Tofacitinib 10 MG [Xeljanz] — full drug profile →
Placebo to match Tofacitinib — full drug profile →

Conditions studied

Diaphragm Injury — all drugs for Diaphragm Injury →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Diaphragm Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.
Richardson PJ, Smith DP, de Giorgio A, Snetkov X, et al · · 2023 · cited 16× · PMID 37828541 · DOI 10.1186/s40035-023-00380-y
Rationale and design of a mechanistic clinical trial of JAK inhibition to prevent ventilator-induced diaphragm dysfunction.
Shrager JB, Wang Y, Lee M, Nesbit S, et al · · 2021 · cited 6× · PMID 34655959 · DOI 10.1016/j.rmed.2021.106620
JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle.
Shrager JB, Randle R, Lee M, Ahmed SS, et al · · 2024 · PMID 39122555 · DOI 10.26508/lsa.202402885

Verify or expand the search:

Other recruiting trials for Diaphragm Injury

Currently open trials in the same condition.

NCT06572280 — Non-invasive Phrenic Nerve Stimulation in ARDS Patient · NA · recruiting
NCT06424314 — Exploration of Mechanisms for Weaning Failure · recruiting
NCT05642832 — Feasibility of Reducing Respiratory Drive Using the Through-flow System · NA · recruiting
NCT05857774 — Respiratory Muscle Structure and Function in Mechanically Ventilated Patients and Long-term Outcomes · recruiting
NCT03667027 — Diaphragm Structure and Pathobiology in Patients Being Bridged to Lung Transplant · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03681275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 25 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03681275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing